Beth Toste Harrison, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2021 | 19153 | 0.800 |
Why?
|
| Receptor, erbB-3 | 1 | 2020 | 131 | 0.760 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2019 | 211 | 0.740 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 198 | 0.710 |
Why?
|
| Gene Fusion | 1 | 2019 | 356 | 0.640 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 141 | 0.610 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 365 | 0.590 |
Why?
|
| Fibroma | 1 | 2016 | 227 | 0.550 |
Why?
|
| Carcinoma | 4 | 2020 | 2353 | 0.540 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2017 | 515 | 0.520 |
Why?
|
| Pleural Effusion | 1 | 2016 | 327 | 0.520 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2018 | 650 | 0.520 |
Why?
|
| Receptor, erbB-2 | 2 | 2020 | 2212 | 0.510 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1085 | 0.510 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 887 | 0.470 |
Why?
|
| Immunohistochemistry | 5 | 2020 | 12095 | 0.460 |
Why?
|
| Breast | 2 | 2017 | 1735 | 0.460 |
Why?
|
| Medical Errors | 1 | 2016 | 1250 | 0.350 |
Why?
|
| Patient Selection | 2 | 2020 | 4381 | 0.330 |
Why?
|
| Endometrial Neoplasms | 3 | 2020 | 1285 | 0.310 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2020 | 289 | 0.300 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 2306 | 0.290 |
Why?
|
| Carcinoma, Lobular | 2 | 2021 | 467 | 0.290 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2021 | 86 | 0.220 |
Why?
|
| Paris | 1 | 2019 | 41 | 0.210 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 4648 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2019 | 301 | 0.190 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 192 | 0.180 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 113 | 0.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 2628 | 0.160 |
Why?
|
| Nipples | 1 | 2018 | 197 | 0.160 |
Why?
|
| Axilla | 1 | 2018 | 509 | 0.160 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 373 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2020 | 1094 | 0.150 |
Why?
|
| Watchful Waiting | 1 | 2019 | 452 | 0.140 |
Why?
|
| Necrosis | 1 | 2019 | 1664 | 0.140 |
Why?
|
| Uterine Hemorrhage | 1 | 2016 | 235 | 0.140 |
Why?
|
| Cytodiagnosis | 1 | 2017 | 413 | 0.130 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 13603 | 0.130 |
Why?
|
| Mucin-1 | 1 | 2017 | 545 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1172 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 1710 | 0.120 |
Why?
|
| Pelvis | 1 | 2016 | 668 | 0.120 |
Why?
|
| Female | 15 | 2021 | 375459 | 0.110 |
Why?
|
| Syndrome | 1 | 2016 | 3178 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 3061 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 2722 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 15407 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2019 | 3059 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3557 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2912 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 19308 | 0.080 |
Why?
|
| Humans | 16 | 2021 | 686663 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2011 | 826 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2020 | 6772 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 8610 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 59331 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9661 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2016 | 5876 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 8070 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2021 | 67320 | 0.050 |
Why?
|
| Middle Aged | 6 | 2020 | 216468 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 2119 | 0.050 |
Why?
|
| Mammography | 2 | 2021 | 2354 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2021 | 1192 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 33186 | 0.040 |
Why?
|
| Aged | 5 | 2020 | 162271 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 1281 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 376 | 0.040 |
Why?
|
| North America | 1 | 2018 | 1169 | 0.040 |
Why?
|
| Adult | 5 | 2020 | 211400 | 0.030 |
Why?
|
| Kinetics | 1 | 2021 | 6979 | 0.030 |
Why?
|
| Mastectomy | 1 | 2021 | 1667 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 56052 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1770 | 0.030 |
Why?
|
| United States | 1 | 2019 | 65579 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 3277 | 0.030 |
Why?
|
| Adolescent | 1 | 2019 | 84957 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3789 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4415 | 0.020 |
Why?
|
| Prognosis | 2 | 2020 | 28923 | 0.020 |
Why?
|
| Male | 2 | 2019 | 352465 | 0.020 |
Why?
|
| Mutation | 2 | 2020 | 28848 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13898 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39737 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2020 | 49071 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 38732 | 0.010 |
Why?
|
| Time Factors | 1 | 2018 | 42271 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 60991 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 69278 | 0.010 |
Why?
|